GlaxoSmithKline PLC Director/PDMR Shareholding (2625I)
April 13 2022 - 4:32AM
UK Regulatory
TIDMGSK
RNS Number : 2625I
GlaxoSmithKline PLC
13 April 2022
GlaxoSmithKline plc (the ' Company ')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Ms E Walmsley
=== ======================== ============================================
b) Position/status Chief Executive Officer
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 7 April 2022 on Ordinary
Shares held in the Company's Performance
Share Plan subject to a 2-year holding
period
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) -----------
GBP17.4100 12,367.170
-----------
=== ======================== ============================================
d) Aggregated information N/A (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2022-04-08
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Mr I Mackay
==== ====================================== ==================================================
b) Position/status Chief Financial Officer
==== ====================================== ==================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ==================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ==================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ==================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ==================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 7 April 2022 on Ordinary
Shares held in the Company's Performance
Share Plan subject to a 2-year holding
period
==== ====================================== ==================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================= ====================
GBP17.4100 2,018.808
===================================================================== ====================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===========================
e) Date of the transaction 2022-04-08
==== ====================================== ==================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ==================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHVXLBFLZLXBBB
(END) Dow Jones Newswires
April 13, 2022 04:32 ET (08:32 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024